Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 8.01 (Other Events), Item 3.02 (Unregistered Sales of Equity Securities), Item 1.01 (Entry into a Material Definitive Agreement). Tarsus acquired iRenix Medical on July 6, 2026, making iRenix a wholly owned subsidiary.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Tarsus acquired iRenix Medical on July 6, 2026, making iRenix a wholly owned subsidiary
- Upfront consideration: $37.5M cash, subject to adjustments, plus 607,093 Tarsus shares
- Additional milestone payments up to $490M tied to regulatory approvals and commercial sales
- Future revenue-sharing obligations: low-to-mid single-digit percentage of net sales for certain products
- Escrow funding supports indemnification obligations and potential merger consideration adjustments
Item 3.02 · Unregistered Sales of Equity Securities
- Stock Consideration issued privately to eligible iRenix stockholders as acquisition-related equity consideration
- Offering limited to accredited investors under Securities Act Section 4(a)(2) and Regulation D exemptions
- Exemption avoids public registration, but creates potential future dilution for existing Tarsus shareholders
Item 8.01 · Other Events
- Tarsus completed an acquisition on July 8, 2026
- Transaction details and strategic rationale contained in Exhibit 99.1
- Completion marks a material corporate event potentially affecting operations and financial outlook
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.